Survival and Associated Factors Among People Living with HIV/AIDS: A 30-year National Survey in Iran

Overview

Journal J Res Med Sci

Specialty General Medicine

Date 2019 Mar 1

PMID 30815018

Citations 11

Authors

Mojtaba Akbari

Mohammad Fararouei

Ali Akbar Haghdoost

Mohammad Mahdi Gouya

Parvin Afsar Kazerooni

Affiliations

Soon will be listed here.

Abstract

Background: The survival in Iranian HIV/AIDS patients based on data from Iran National HIV/AIDS Case Registry System has not been evaluated. This study assessed the survival rates and associated factors among people living with HIV/AIDS in Iran.

Materials And Methods: The population in this observational study included 32168 patients diagnosed with HIV/AIDS registered in Iran disease registry system between 1986 and 31 December 2015. Data until June 2016 (the cutoff date of our last data linkage) were investigated to estimate survival and related factors following HIV diagnosis.

Results: Of registered patients, 17.7% were diagnosed at AIDS stage. By June 2016, 27.2% of study population progressed to AIDS, and 8081 (25.1%) of patients died. The survival rate was 88%, 85%, 77%, and 67% for 1, 2, 5, and 10 years, respectively. Cumulative proportion surviving was significantly lower in males than in females ( = 0.0001). A higher rate of survival was seen in female patients, who diagnosed after 2010, infected in sexual route, and had CD4 cell count more than 500, nonconfected patients with tuberculosis (TB), and those who received antiretroviral therapy (ART). Based on multivariate model, the mortality risk in female patients, those with CD4 cell count more than 500, patients who received ART, and those with TB and injection drug uses (IDUs) was higher.

Conclusion: The survival in studied patients increased in recent time periods, and ART reduced AIDS-related mortality in these patients. The survival can be increased by focus on improvements in patient care among male patients, IDUs, and patients with TB coinfection.

Citing Articles

Cost-effectiveness of pretreatment HIV drug resistance testing in people living with HIV in Iran.

Mirzaei H, Iranpour A, Esmaeilzadeh F, Barouni M, Mehrabi F, Ranjbar E PLoS One. 2024; 19(9):e0309528.

PMID: 39240944 PMC: 11379287. DOI: 10.1371/journal.pone.0309528.

Handgrip Strength and Clinical Evolution of People Living with HIV: A Mini Narrative Review.

Gouvea-E-Silva L, de Morais L, de Souza Goncalves G, Siqueira M, Lima V, Cardoso L Curr HIV Res. 2024; 22(4):213-218.

PMID: 39113304 DOI: 10.2174/011570162X306973240802104449.

Survival Analysis of Antiretroviral Treatment for PLWH in Sichuan Province, China, 2003-2022: A Large Retrospective Cohort Study.

Ye L, Sun X, Li Y, Zeng Y, Zhuoma L, Zhou D Infect Drug Resist. 2024; 17:3133-3143.

PMID: 39050836 PMC: 11268743. DOI: 10.2147/IDR.S463262.

What may encourage or deter health services utilization by people living with or at the risk of HIV/AIDS in special health centers? Qualitative evidence from a stigmatized community.

Bazyar M, Tahmasebi Ghorabi S, Sadeghifar J, Ranjbar M, Pakzad R, Bonyadi F BMC Public Health. 2024; 24(1):981.

PMID: 38589818 PMC: 11000400. DOI: 10.1186/s12889-024-18480-3.

Pattern of contributing behaviors and their determinants among people living with HIV in Iran: A 30-year nationwide study.

Gheibi Z, Fararouei M, Afrashteh S, Akbari M, Kazerooni P, Shokoohi M Front Public Health. 2023; 11:1038489.

PMID: 36908430 PMC: 9998994. DOI: 10.3389/fpubh.2023.1038489.

References

Jerene D, Naess A, Lindtjorn B . Antiretroviral therapy at a district hospital in Ethiopia prevents death and tuberculosis in a cohort of HIV patients. AIDS Res Ther. 2006; 3:10. PMC: 1475602. DOI: 10.1186/1742-6405-3-10. View

Walensky R, Paltiel A, Losina E, Mercincavage L, Schackman B, Sax P . The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006; 194(1):11-9. DOI: 10.1086/505147. View

Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S . Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr. 2006; 43(1):42-6. DOI: 10.1097/01.qai.0000230521.86964.86. View

Hall H, McDavid K, Ling Q, Sloggett A . Determinants of progression to AIDS or death after HIV diagnosis, United States, 1996 to 2001. Ann Epidemiol. 2006; 16(11):824-33. DOI: 10.1016/j.annepidem.2006.01.009. View

Lima V, Hogg R, Harrigan P, Moore D, Yip B, Wood E . Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS. 2007; 21(6):685-92. DOI: 10.1097/QAD.0b013e32802ef30c. View

Ojikutu B, Zheng H, Walensky R, Lu Z, Losina E, Giddy J . Predictors of mortality in patients initiating antiretroviral therapy in Durban, South Africa. S Afr Med J. 2008; 98(3):204-8. PMC: 2408889. View

Kigozi B, Sumba S, Mudyope P, Namuddu B, Kalyango J, Karamagi C . The effect of AIDS defining conditions on immunological recovery among patients initiating antiretroviral therapy at Joint Clinical Research Centre, Uganda. AIDS Res Ther. 2009; 6:17. PMC: 2731026. DOI: 10.1186/1742-6405-6-17. View

Kee M, Lee J, Kim E, Lee J, Nam J, Yoo B . Improvement in survival among HIV-infected individuals in the Republic of Korea: need for an early HIV diagnosis. BMC Infect Dis. 2009; 9:128. PMC: 2738677. DOI: 10.1186/1471-2334-9-128. View

Boulle A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M, Mathee S . Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS. 2010; 24(4):563-72. DOI: 10.1097/QAD.0b013e328333bfb7. View

10.

Johansson K, Robberstad B, Norheim O . Further benefits by early start of HIV treatment in low income countries: survival estimates of early versus deferred antiretroviral therapy. AIDS Res Ther. 2010; 7(1):3. PMC: 2836271. DOI: 10.1186/1742-6405-7-3. View

11.

Banerjee T, Pensi T, Banerjee D, Grover G . Impact of HAART on survival, weight gain and resting energy expenditure in HIV-1-infected children in India. Ann Trop Paediatr. 2010; 30(1):27-37. DOI: 10.1179/146532810X12637745451915. View

12.

May M, Boulle A, Phiri S, Messou E, Myer L, Wood R . Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet. 2010; 376(9739):449-57. PMC: 3138328. DOI: 10.1016/S0140-6736(10)60666-6. View

13.

Cornell M, Grimsrud A, Fairall L, Fox M, Van Cutsem G, Giddy J . Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS. 2010; 24(14):2263-70. PMC: 2948209. DOI: 10.1097/QAD.0b013e32833d45c5. View

14.

Alemu A, San Sebastian M . Determinants of survival in adult HIV patients on antiretroviral therapy in Oromiyaa, Ethiopia. Glob Health Action. 2010; 3. PMC: 2967337. DOI: 10.3402/gha.v3i0.5398. View

15.

Mahy M, Stover J, Stanecki K, Stoneburner R, Tassie J . Estimating the impact of antiretroviral therapy: regional and global estimates of life-years gained among adults. Sex Transm Infect. 2010; 86 Suppl 2:ii67-71. PMC: 3173805. DOI: 10.1136/sti.2010.046060. View

16.

Yao S, Duan S, Xiang L, Ye R, Yang Y, Li Y . [Survival analysis on 3103 HIV/AIDS patients receiving antiretroviral treatment in Dehong prefecture, Yunnan province]. Zhonghua Liu Xing Bing Xue Za Zhi. 2010; 31(11):1215-8. View

17.

Dowdy D, Geng E, Christopoulos K, Kahn J, Hare C, Wlodarczyk D . Mortality among antiretroviral-eligible patients in an urban public clinic. J Acquir Immune Defic Syndr. 2011; 57(4):297-300. PMC: 3159809. DOI: 10.1097/QAI.0b013e31822233aa. View

18.

Gupta A, Nadkarni G, Yang W, Chandrasekhar A, Gupte N, Bisson G . Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One. 2012; 6(12):e28691. PMC: 3248405. DOI: 10.1371/journal.pone.0028691. View

19.

Biadgilign S, Reda A, Digaffe T . Predictors of mortality among HIV infected patients taking antiretroviral treatment in Ethiopia: a retrospective cohort study. AIDS Res Ther. 2012; 9(1):15. PMC: 3403909. DOI: 10.1186/1742-6405-9-15. View

20.

Mageda K, Leyna G, Mmbaga E . High Initial HIV/AIDS-Related Mortality and -Its Predictors among Patients on Antiretroviral Therapy in the Kagera Region of Tanzania: A Five-Year Retrospective Cohort Study. AIDS Res Treat. 2012; 2012:843598. PMC: 3437609. DOI: 10.1155/2012/843598. View